基于蛋白质的 MRI 对比剂用于前列腺癌的分子成像。
Protein-based MRI contrast agents for molecular imaging of prostate cancer.
机构信息
Department of Chemistry and Biology, Georgia State University, Atlanta, GA, 30302, USA.
Biotechnology Core Facility Branch, Center for Disease Control and Prevention, Atlanta, GA, 30333, USA.
出版信息
Mol Imaging Biol. 2011 Jun;13(3):416-423. doi: 10.1007/s11307-010-0342-9.
PURPOSE
The purpose of this study was to demonstrate a novel protein-based magnetic resonance imaging (MRI) contrast agent that has the capability of targeting prostate cancer and which provides high-sensitivity MR imaging in tumor cells and mouse models.
PROCEDURE
A fragment of gastrin-releasing peptide (GRP) was fused into a protein-based MRI contrast agent (ProCA1) at different regions. MR imaging was obtained in both tumor cells (PC3 and H441) and a tumor mouse model administrated with ProCA1.GRP.
RESULTS
PC3 and DU145 cells treated with ProCA1.GRPs exhibited enhanced signal in MRI. Intratumoral injection of ProCA1.GRP in a PC3 tumor model displayed enhanced MRI signal. The contrast agent was retained in the PC3 tumor up to 48 h post-injection.
CONCLUSIONS
Protein-based MRI contrast agent with tumor targeting modality can specifically target GRPR-positive prostate cancer. Intratumoral injection of the ProCA1 agent in the prostate cancer mouse model verified the targeting capability of ProCA1.GRP and showed a prolonged retention time in tumors.
目的
本研究旨在展示一种新型基于蛋白质的磁共振成像（MRI）对比剂，该对比剂具有靶向前列腺癌的能力，并能在肿瘤细胞和小鼠模型中提供高灵敏度的 MRI 成像。
方法
将胃泌素释放肽（GRP）的片段融合到基于蛋白质的 MRI 对比剂（ProCA1）的不同区域。在接受 ProCA1.GRP 处理的肿瘤细胞（PC3 和 H441）和肿瘤小鼠模型中进行了 MRI 成像。
结果
用 ProCA1.GRPs 处理的 PC3 和 DU145 细胞在 MRI 中显示出增强的信号。在 PC3 肿瘤模型中，经皮腔内注射 ProCA1.GRP 显示出增强的 MRI 信号。该对比剂在注射后 48 小时内仍保留在 PC3 肿瘤中。
结论
具有肿瘤靶向方式的基于蛋白质的 MRI 对比剂可以特异性地靶向 GRPR 阳性前列腺癌。在前列腺癌小鼠模型中经皮腔内注射 ProCA1 剂验证了 ProCA1.GRP 的靶向能力，并显示出在肿瘤中的延长保留时间。
Zotero 插件